Plasma antioxidants and brain glucose metabolism in elderly subjects with cognitive complaints

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 4, 2014, Pages 764-775

  Picco, Agnese ^a   Polidori, M Cristina ^b   Ferrara, Michela ^a   Cecchetti, Roberta ^c   Arnaldi, Dario ^a   Baglioni, Mauro ^c   Morbelli, Silvia ^a   Bastiani, Patrizia ^c   Bossert, Irene ^a   Fiorucci, Giuliana ^d   Brugnolo, Andrea ^a   Dottorini, Massimo Eugenio ^d   Nobili, Flavio ^a   Mecocci, Patrizia ^c  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF PERUGIA   (Italy)

^d Department of Cardiology   (Italy)

Author keywords

Alzheimer's disease; Brain FDG PET; Mild cognitive impairment; Oxidative stress; Subjective cognitive impairment; Superoxide dismutase

Indexed keywords

CATALASE; EXTRACELLULAR SUPEROXIDE DISMUTASE; FLUORODEOXYGLUCOSE F 18; GLUCOSE; GLUTATHIONE PEROXIDASE; RADIOPHARMACEUTICAL AGENT; SUPEROXIDE DISMUTASE;

AGED; ALZHEIMER DISEASE; ANTIOXIDANT ASSAY; ARTICLE; BRAIN SCINTISCANNING; CLINICAL DEMENTIA RATING; COGNITIVE DEFECT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIGITAL IMAGING AND COMMUNICATIONS IN MEDICINE; FEMALE; GERIATRIC DISORDER; GLUCOSE BLOOD LEVEL; GLUCOSE BRAIN LEVEL; GLUCOSE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; OXIDATIVE STRESS; PET-CT SCANNER; PSYCHOLOGIC TEST; SUBJECTIVE COGNITIVE IMPAIRMENT; VOXEL BASED MORPHOMETRY; BLOOD; BRAIN; DIAGNOSTIC USE; METABOLISM; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; CATALASE; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; GLUTATHIONE PEROXIDASE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; OXIDATIVE STRESS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SUPEROXIDE DISMUTASE;

EID: 84897027999     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2638-x     Document Type: Article

References (61)

1. Butterfield DA, Swomley AM, Sultana R. Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxid Redox Signal. 2013;19:823-35.
2. Smith MA, Nunomura A, Lee HG, Zhu X, Moreira PI, Avila J, et al. Chronological primacy of oxidative stress in Alzheimer's disease. Neurobiol Aging. 2005;26:579-80. (Pubitemid 40228747)
3. Cadenas E. Mitochondrial free radical production and cell signaling. Mol Aspects Med. 2004;25:17-26. (Pubitemid 38401928)
4. Fukai T, Ushio-Fukai M. Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid Redox Signal. 2011;15:1583-606.
5. Padurariu M, Ciobica A, Hritcu L, Stoica B, Bild W, Stefanescu C. Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett. 2010;469:6-10.
6. Sies H, Cadenas E. Oxidative stress: damage to intact cells and organs. Philos Trans R Soc Lond B Biol Sci. 1985;311:617-31.
7. Tamagno E, Parola M, Bardini P, Piccini A, Borghi R, Guglielmotto M, et al. Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J Neurochem. 2005;92:628-36. (Pubitemid 40189465)
8. Tamagno E, Guglielmotto M, Aragno M, Borghi R, Autelli R, Giliberto L, et al. Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein. J Neurochem. 2008;104:683-95.
9. Butterfield DA, Griffin S, Munch G, Pasinetti G. Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. J Alzheimers Dis. 2002;4:193-201. (Pubitemid 35006051)
10. Behl C. Oxidative stress in Alzheimer's disease: implications for prevention and therapy. Subcell Biochem. 2005;38:65-78.
11. Gòmez-Ramos A, Dìaz-Nido J, Smith MA, Perry G, Avila J. Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. J Neurosci Res. 2003;71:863-70. (Pubitemid 36293007)
12. Zhu X, Rottkamp CA, Boux H, Takeda A, Perry G, Smith MA. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol. 2000;59:880-8.
13. Ames BN. Delaying the mitochondrial decay of aging. Ann N Y Acad Sci. 2004;1019:406-11. (Pubitemid 38951346)
14. Mariani E, Polidori MC, Cherubini A, Mecocci P. Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;827:65-75. (Pubitemid 41551598)
15. Allaman I, Bélanger M, Magistretti PJ. Astrocyte-neuron metabolic relationships: for better and for worse. Trends Neurosci. 2011;34:76- 87.
16. Massaad CA, Pautler RG, Klann E. Mitochondrial superoxide: a key player in Alzheimer's disease. Aging (Albany NY). 2005;1:758-61.
17. Faraci FM. Protecting against vascular disease in brain. Am J Physiol Heart Circ Physiol. 2011;300:H1566-82.
18. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjögren M, et al. European task force on age-related white matter changes. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32:1318-22. (Pubitemid 32530416)
19. Katz S, Downs TD, Cash HR, Grotz RC. Progress in development of the index of ADL. Gerontologist. 1970;10:20-30.
20. Lawton MP, Brody EM. Assessment of older people; self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179 - 86.
21. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-98.
22. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263-9.
23. Loeb C, Gandolfo C. Diagnostic evaluation of degenerative and vascular dementia. Stroke. 1983;14:399-401. (Pubitemid 13100322)
24. Rey A. L' examenclinique en psychologie. Paris: Presses Universitaires de France; 1958.
25. Novelli G, Papagno C, Capitani E, Laiacona M, Cappa SF. Tre test clinici di memoria verbale a lungo termine: taratura su soggetti normali. Arch Psicol Neurol Psichiatria. 2013;47:278-96.
26. Carlesimo GA, Caltagirone C, Gainotti G. The mental deterioration battery: normative data, diagnostic reliability and qualitative analysis of cognitive impairment. The group for the standardization of the mental deterioration battery. Eur Neurol. 1996;36:378-84. (Pubitemid 26343685)
27. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183-94. (Pubitemid 39222988)
28. L'Abbé MR, Fisher PWF. Automated assay of superoxide dismutase in blood. Methods Enzymol. 1990;186:232-7. (Pubitemid 20279961)
29. Sandström J, Nilsson P, Karlsson K, Marklund SL. 10-fold increase in human plasma extracellular superoxide dismutase content caused by a mutation in heparin-binding domain. J Biol Chem. 1994;269:19163-6. (Pubitemid 24226241)
30. Zhou LC, Xiang W, Potts J, Floyd M, Sharan C, Yang H, et al. Reduction in extracellular superoxide dismutase activity in African-American patients with hypertension. Free Radic Biol Med. 2006;41: 1384-91. (Pubitemid 44466723)
31. Flohé L, Günzler WA. Assays of glutathione peroxidase. Methods Enzymol. 1984;105:114-21. (Pubitemid 14165378)
32. Beers RF, Sizer IW. A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. J Biol Chem. 1952;195:133-40.
33. Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, Någren K, et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging. 2009;36:2103- 10.
34. Morbelli S, Drzezga A, Perneczky R, Frisoni GB, Caroli A, Van Berckel BN, et al. Resting metabolic connectivity in prodromal Alzheimer's disease. A European Alzheimer Disease Consortium (EADC) project. Neurobiol Aging. 2012;33:2533-50.
35. Gispert JD, Pascau J, Reig S, Martínez-Lázaro R, Molina V, García-Barreno P, et al. Influence of the normalization template on the outcome of statistical parametric mapping of PET scans. Neuroimage. 2003;19:601-12. (Pubitemid 36918206)
36. Oishi N, Udaka F, Kameyama M, Sawamoto N, Hashikawa K, Fukuyama H. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology. 2005;65:1708-15.
37. Rodriguez G, Morbelli S, Brugnolo A, Calvini P, Girtler N, Piccardo A, et al. Global cognitive impairment should be taken into account in SPECT-neuropsychology correlations: the example of verbal memory in very mild Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2005;32:1186-92. (Pubitemid 41355945)
38. Zelko IN, Mariani TJ, Folz RJ. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic Biol Med. 2002;33:337-49. (Pubitemid 34790245)
39. Tasaki H, Yamashita K, Tsutsui M, Kamezaki F, Kubara T, Tanaka S, et al. Heparin-released extracellular superoxide dismutase is reduced in patients with coronary artery atherosclerosis. Atherosclerosis. 2006;187:131-8. (Pubitemid 43817005)
40. De la Torre JC. Alzheimer's disease: how does it start? J Alzheimers Dis. 2002;4:497-512. (Pubitemid 36142839)
41. Polidori MC, Pientka L. Bridging the pathophysiology of Alzheimer's disease with vascular pathology: the feed-back, the feed-forward, and oxidative stress. J Alzheimers Dis. 2012;28:1-9.
42. Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, et al. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging. 2003;24:915-9. (Pubitemid 36962976)
43. Baumbach GL, Didion SP, Faraci FM. Hypertrophy of cerebral arterioles in mice deficient in expression of the gene for CuZn superoxide dismutase. Stroke. 2006;37:1850-5. (Pubitemid 44297741)
44. Didion SP, Hathaway CA, Faraci FM. Superoxide levels and function of cerebral blood vessels after inhibition of CuZn-SOD. Am J Physiol Heart Circ Physiol. 2001;281:H1697-703.
45. Yada T, Shimokawa H, Morikawa K, Takaki A, Shinozaki Y, Mori H, et al. Role of Cu, Zn-SOD in the synthesis of endogenous vasodilator hydrogen peroxide during reactive hyperemia in mouse mesenteric microcirculation in vivo. Am J Physiol Heart Circ Physiol. 2008;294:H441-8.
46. Demchenko IT, Gutsaeva DR, Moskvin AN, Zhilyaev SY. Involvement of extracellular superoxide dismutase in regulating brain blood flow. Neurosci Behav Physiol. 2010;40:173-8.
47. Federico A, Cardaioli E, Da Pozzo P, Formichi P, Gallus GN, Radi E. Mitochondria, oxidative stress and neurodegeneration. J Neurol Sci. 2012;322:254-62.
48. Rajagopalan P, Toga AW, Jack CR, Weiner MW, Thompson PM. Fat-mass-related hormone, plasma leptin, predicts brain volumes in the elderly. Neuroreport. 2013;24:58-62.
49. Toledo JB, Da X, Bhatt P, Wolk DA, Arnold SE, Shaw LM. Relationship between plasma analytes and SPARE-AD defined brain atrophy patterns in ADNI. PLoS One. 2013;8:e55531.
50. den Heijer T, Vermeer SE, Clarke R, Oudkerk M, Koudstaal PJ, Hofman A, et al. Homocysteine and brain atrophy on MRI of non-demented elderly. Brain. 2003;126:170-5. (Pubitemid 36068567)
51. Terni B, Boada J, Portero-Otin M, Pamplona R, Ferrer I. Mitochondrial ATP-synthase in the entorhinal cortex is a target of oxidative stress at stages I/II of Alzheimer's disease pathology. Brain Pathol. 2010;20:222-33.
52. Limón ID, Díaz A, Mendieta L, Chamorro G, Espinosa B, Zenteno E, et al. Amyloid-beta(25-35) impairs memory and increases NO in the temporal cortex of rats. Neurosci Res. 2009;63:129-37.
53. Wang J, Xiong S, Xie C, Markesbery WR. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. J Neurochem. 2005;93:953-62. (Pubitemid 40695754)
54. Sultana R, Butterfield DA. Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment. J Bioenerg Biomembr. 2009;41:441-6.
55. Hovorkova P, Kristofikova Z, Horinek A, Ripova D, Majer E, Zach P, et al. Lateralization of 17beta-hydroxysteroid dehydrogenase type 10 in hippocampi of demented and psychotic people. Dement Geriatr Cogn Disord. 2008;26:193-8.
56. Waldbaum S, Patel M. Mitochondrial oxidative stress in temporal lobe epilepsy. Epilepsy Res. 2010;88:23-45.
57. Morbelli S, Piccardo A, Villavecchia G, Dessi B, Brugnolo A, Piccini A, et al. Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study. Eur J Nucl Med Mol Imaging. 2010;37:36-45.
58. Bozzali M, Padovani A, Caltagirone C, Borroni B. Regional grey matter loss and brain disconnection across Alzheimer disease evolution. Curr Med Chem. 2011;18:2452-8.
59. Bozoki AC, Korolev IO, Davis NC, Hoisington LA, Berger KL. Disruption of limbic white matter pathways in mild cognitive impairment and Alzheimer's disease: a DTI/FDG-PET study. Hum Brain Mapp. 2012;33:1792-802.
60. Grimmer T, Faust M, Auer F, Alexopoulos P, Förstl H, Henriksen G, et al. White matter hyperintensities predict amyloid increase in Alzheimer's disease. Neurobiol Aging. 2012;33:2766-73.
61. Clausen A, Xu X, Bi X, Baudry M. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline. J Alzheimers Dis. 2012;30:183-208.